HER2 status in gastric cancers: A retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2360-2364

  Sheng, W Q ^a,b   Huang, D ^a,b   Ying, J M ^c   Lu, N ^c   Wu, H M ^d   Liu, Y H ^d   Liu, J P ^e   Bu, H ^e   Zhou, X Y ^a,b   Du, Xiang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c CANCER HOSPITAL   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e SICHUAN UNIVERSITY   (China)

Author keywords

Dual SISH; FISH; Gastric cancer; HER2; Immunohistochemistry; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BRIGHT FIELD DUAL COLOR SILVER IN SITU HYBRIDIZATION; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CELL HETEROGENEITY; CHINA; CHINESE; CHROMOSOME NUMBER; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYSOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER; TUMOR LOCALIZATION;

DUAL SISH; FISH; GASTRIC CANCER; HER2; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

CHINA; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84883434765     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt232     Document Type: Article

References (26)

1. Shanghai Municipal Center for Disease Control and Prevention. Shanghai Cancer Report 2010. Shanghai: SCDC 2010.
2. Ferlay J, Bray F, Pisani P et al GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5.version 2.0. Lyon: IARC 2004.
3. Horner MJ, Ries LAG, Krapcho M et al SEER Cancer Statistics Review, 1975-2006. 2009. http://seer.cancer.gov/csr/1975_2006/(12 April 2009, date last accessed).
4. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
5. Hoffmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: result from a validation study. Histopathology 2008; 52: 797-805.
6. European Medicines Agency. Opinion. www.emea.europa.eu/pdfs/human/opinion/Herceptin_82246709en.pdf> 2009 (6 May 2013, date last accessed).
7. Sakai K, Mori S, Kawamoto T et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986; 77: 1047-1052.
8. Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer 2012; 3: 137-144.
9. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010; 63: 839-842.
10. Lee KE, Lee H-J, Kim YH, et al. Prognostic significance of p53, nm23, PCNA and cerbB- 2 in gastric cancer. Jpn J Clin Oncol 2003; 33: 173-179.
11. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value: conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65.
12. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278.
13. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386-1393.
14. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71.
15. Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013; 6: 1448-1457.
16. RuschoffJ, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25: 637-650.
17. HERCEPTIN® (trastuzumab). www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf> 2010 (6 May 2013, date last accessed).
18. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma. Comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010; 34: 767-776.
19. Garcia-Garcia E, Gomez-Martin C, Angulo B, et al. Hybridization for HER2 testing in gastric carcinoma: a comparison of fluorescence in situ hybridization with a novel fully automated dual-color silver in situ hybridization. Histopathology 2011; 59: 8-17.
20. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009; 22: 1169-1175.
21. Chung HC, Bang YJ, Xu JM, et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing. Eur J Cancer 2009; 7(suppl): 364-364.
22. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992; 10: 1044-1048.
23. Seshadri R, Horsfall DJ, Firgaira F, et al. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Group. Int J Cancer 1994; 56: 61-65.
24. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235: 177-182.
25. Jain S, Filipe MI, Gullick WJ, et al. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991; 48: 668-671.
26. Gomez-Martin C, Garralda E, Echarri MJ, et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 2012; 65: 751-757.